

Production Department Senior Manager wins “8th Annual Achievement Award for the Development of Female Technologists”

Japan Tissue Engineering Co., Ltd. (“J-TEC”, headquarters in Gamagori, Aichi, Japan; President & CEO, Ken-ichiro Hata) is pleased to announce that Miho Fujita, Ph.D, Senior Manager of our Production Department, has received the “8th Annual Achievement Award for the Development of Female Technologists” sponsored by the Japan Association of Technology Executives (JAOTEX).

The Achievement Award for the Development of Female Technologists is awarded by JAOTEX to commend prominent individual achievements in the development of female technologists. Since its inception in 2014, the award has been received by executive officers and managers of famous major corporations as well as medium- and small-sized businesses. JAOTEX has taken the initiative in supporting the Japanese national government’s goal of “increasing the proportion of women in leadership positions to 30% by 2030” and is engaged in activities to support the promotion and appointment of female technologists to leadership positions in industry.

This year’s award winner Miho Fujita, Ph.D. initially followed a dual-track career in our R&D Department and Quality Control Department after joining J-TEC. She was promoted to Senior Manager of the Production Department in 2019, since when she has striven to construct a system for educating the female technologists who account for the majority of members in that department. Along with recommending that J-TEC’s employees involved in manufacturing obtain the Clinical Cultivist qualification certified by the Japanese Society for Regenerative Medicine to acquire advanced culturing techniques, she has introduced a new Cell Culture Meister System as an in-house qualification to give employees stronger technical skills and the ability to lead, while also heightening their motivation.

Moreover, to cope with the closure of nurseries and schools during the COVID-19 pandemic, Ms. Fujita set up a limited-time day-care center within the company to support women working shortened hours following maternity and childcare leave. She has drawn upon her experience and knowledge of the concerns of working women to foster a climate of “consideration for each other” within J-TEC and promote the creation of an environment in which female technologists can continue to work long term after maternity and childcare leave by helping each other.

Ms. Fujita has received this award in recognition of these activities.



At the Award Ceremony on August 10, 2022 (Fujita is second from the left in the middle row)

With the vision of “Creating a future for regenerative medicine”, J-TEC continues to challenge new horizons in the transformation of regenerative medicine into a full-fledged industry. Approximately 60% of J-TEC’s employees and 30% of its managers are female, and we are proactively promoting the social involvement of women. To help achieve the Sustainable Development Goal of “Gender Equality”, J-TEC will continue contributing in various forms to the realization of a society in which men and women participate equally.

Overview of the “8th Annual Achievement Award for the Development of Female Technologists”

Sponsored by: Japan Association of Technology Executives
Cosponsored by: NPO Japan Women's Innovative Network (J-Win)
Supported by: Gender Equality Bureau Cabinet Office; Ministry of Economy, Trade and Industry; Ministry of Health, Labour and Welfare; Ministry of Land, Infrastructure, Transport and Tourism

Visit the website of the Japan Association of Technology Executives (Japanese language only) at <https://jaotex.or.jp/>

(Reference: About J-TEC)

J-TEC is a maker of regenerative medical products whose corporate vision is “creating a future for regenerative medicine,” and has been a member of the Teijin Group since March 2021.

As Japan’s top runner in regenerative medicine, J-TEC obtained marketing approval for autologous cultured epidermis “JACE”, Japan’s first regenerative medical product, in October of 2007, and began marketing the product in January of 2009. J-TEC then went on to obtain marketing approval for Autologous Cultured Cartilage “JACC” in July of 2012, for Autologous Cultured Corneal Epithelium “Nepic” in March of 2020, and for Autologous Cultured Oral Mucosal Epithelium “Ocural” in June 2021. “JACC” was Japan’s first regenerative medical product for use in orthopedic surgery, and “Nepic” was the first for use in ophthalmology. Of the 16 regenerative medical products that have been approved in Japan, four are J-TEC products.

[Contact information for inquiries about this announcement]

Japan Tissue Engineering Co., Ltd.
TEL 0533-66-2020
E-mail jtec-info@jpte.co.jp